Ratings Sanofi

Equities

Market Closed - Euronext Paris Other stock markets 09:07:50 15/07/2025 pm IST			After hours 09:24:09 pm
82.70 ^EUR	-1.01%		82.66	-0.05%

11/07	SANOFI : UBS reiterates its Buy rating	ZD
11/07	Delaware Supreme Court sides with Zantac drugmakers over cancer evidence	RE

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The company returns high margins, thereby supporting business profitability.
The company is one of the best yield companies with high dividend expectations.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Source: Surperformance

Source: MSCI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	SANOFI				12TCr
	ELI LILLY AND COMPANY				72TCr
	JOHNSON & JOHNSON				38TCr
	ABBVIE INC.				34TCr
	NOVO NORDISK A/S				31TCr
	ROCHE HOLDING AG				26TCr
	NOVARTIS AG				24TCr
	ASTRAZENECA PLC				22TCr
	MERCK & CO., INC.				21TCr
	AMGEN INC.				16TCr
	Average				29.49TCr
	Weighted average by Cap.